Skip to main content

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention

Objective

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.

Field of science

  • /medical and health sciences/basic medicine/neurology/stroke
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

DEUTSCHES HERZZENTRUM MUNCHEN
Address
Lazarettstrasse 36
80636 Munich
Germany
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
EU contribution
€ 853 354,30
Administrative Contact
Per Larsen (Mr.)

Participants (12)

UNIVERSITY OF LEICESTER
United Kingdom
EU contribution
€ 825 270
Address
University Road
LE1 7RH Leicester
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marie Adams (Mrs.)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 503 040
Address
Geschwister Scholl Platz 1
80539 Muenchen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Martin Dichgans (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 354 560
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Stephen Conway (Dr.)
UNIVERSITAET zu LUEBECK
Germany
EU contribution
€ 336 080
Address
Ratzeburger Allee 160
23562 Lubeck
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Nadine Clausen (Dr.)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 609 720
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karin Krol-Simons (Mrs.)
BIOCEROS BV

Participation ended

Netherlands
EU contribution
€ 282 763,20
Address
Yalelaan 46
3584 CM Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Remco Brandt (Mr.)
European ScreeningPort GmbH
Germany
EU contribution
€ 60 836,50
Address
Schnackenburgallee
22525 Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Philip Gribbon (Dr.)
CLINICAL GENE NETWORKS AB
Sweden
EU contribution
€ 397 748,20
Address
Karolinska Sience Park - Fogdevreten 2
171 77 Stockholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Johan Björkegren (Prof.)
4SC DISCOVERY GMBH
Germany
EU contribution
€ 454 260
Address
Am Klopferspitz 19A
82152 Planegg Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stefan Strobl (Dr.)
GENEDATA AG
Switzerland
EU contribution
€ 374 062,50
Address
Margarethenstrasse 38
4053 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Timo Wittenberger (Dr.)
Horizon Discovery Limited
United Kingdom
EU contribution
€ 240 179,20
Address
Cambridge Research Park
CB25 9TL Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Dirk Gewert (Mr.)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 703 575,10
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Michael Prestele (Mr.)